Rosalyn A. Juergens, Ph.D.
Affiliations: | 2012 | Johns Hopkins University, Baltimore, MD |
Area:
OncologyGoogle:
"Rosalyn Juergens"Parents
Sign in to add mentor| Richard Ambinder | grad student | 2012 | Johns Hopkins | |
| (Targeting epigenetic changes in non-small cell lung cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Goss G, Ciuleanu T, Ramlau R, et al. (2025) Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study. Therapeutic Advances in Medical Oncology. 17: 17588359251332154 |
| Melosky B, Juergens RA, Banerji S, et al. (2025) The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 17: 17588359241308784 |
| Brade AM, Bahig H, Bezjak A, et al. (2024) Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process. Current Oncology (Toronto, Ont.). 31: 6512-6535 |
| Chan SWS, Zeng J, Young J, et al. (2024) A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer. Clinical Lung Cancer |
| Bonert M, Schittenhelm J, Begum H, et al. (2024) Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers. Plos One. 19: e0314205 |
| Breadner D, Hwang DM, Husereau D, et al. (2024) Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective. Current Oncology (Toronto, Ont.). 31: 6017-6031 |
| Barghout SH, Zhan LJ, Raptis S, et al. (2024) Treatment patterns and outcomes in KRAS-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study. Lung Cancer (Amsterdam, Netherlands). 194: 107898 |
| Melosky B, Vincent MD, McGuire AL, et al. (2024) Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer. International Journal of Cancer |
| Esfahanian N, Chan SWS, Zhan LJ, et al. (2023) Presentation and outcomes of KRAS mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence. Cancer Treatment and Research Communications. 37: 100774 |
| Anagnostou V, Ho C, Nicholas G, et al. (2023) ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nature Medicine. 29: 2559-2569 |